{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T02:30:48Z","timestamp":1787538648380,"version":"build-2736575974"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Practitioner Fellowship (APP1141295)"],"award-info":[{"award-number":["Practitioner Fellowship (APP1141295)"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["Program Grant (APP1093017)"],"award-info":[{"award-number":["Program Grant (APP1093017)"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Patients presenting with early-stage melanoma (AJCC pT1b-pT2a) reportedly have a relatively low risk of a positive SNB (~5\u201310%). Those patients are usually found to have low-volume metastatic disease after SNB, typically reclassified to AJCC stage IIIA, with an excellent prognosis of ~90% 5-year survival. Currently, adjuvant systemic therapy is not routinely recommended for most patients with AJCC stage IIIA melanoma. The purpose was to assess the SN-positivity rate in early-stage melanoma and to identify primary tumor characteristics associated with high-risk nodal disease eligible for adjuvant systemic therapy<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An international, multicenter retrospective cohort study from 7 large-volume cancer centers identified 3,610 patients with early primary cutaneous melanomas 0.8\u20132.0 mm in Breslow thickness (pT1b-pT2a; AJCC 8th edition). Patient demographics, primary tumor characteristics, and SNB status\/details were analyzed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall SNB-positivity rate was 11.4% (412\/3610). Virtually all SNB-positive patients (409\/412; 99.3%) were reclassified to AJCC stage IIIA. Multivariate analysis identified age, T-stage, mitotic rate, primary site and subtype, and lymphovascular invasion as independent predictors of sentinel node status. A mitotic rate of &gt;1\/mm<jats:sup>2<\/jats:sup> was associated with a significantly increased SN-positivity rate and was the only significant independent predictor of high-risk SNB metastases (&gt;1 mm maximum diameter).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The new treatment paradigm brings into question the role of SNB for patients with early-stage melanoma. The results of this large international cohort study suggest that a reevaluation of the indications for SNB for some patients with early-stage melanoma is required.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-11761-4","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T19:14:05Z","timestamp":1652469245000},"page":"5937-5945","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluation of the Indications for Sentinel Node Biopsy in Early-Stage Melanoma with the Advent of Adjuvant Systemic Therapy: An International, Multicenter Study"],"prefix":"10.1245","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4492-235X","authenticated-orcid":false,"given":"Marc D.","family":"Moncrieff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serigne N.","family":"Lo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Scolyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J.","family":"Heaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny P.","family":"Nobes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew P.","family":"Snelling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Nessim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryckie","family":"Wade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Howard","family":"Peach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumi","family":"Kisyova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan D.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rowan","family":"Pritchard Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vernon K.","family":"Sondak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"11761_CR1","doi-asserted-by":"crossref","unstructured":"Gershenwald JE, Scolyer RA, Hess KR et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual: Melanoma Staging: AJCC 8 th Edition. CA Cancer J Clin, 2017;67(6):472\u201392","DOI":"10.3322\/caac.21409"},{"key":"11761_CR2","unstructured":"Melanoma: Cutaneous. NCCN Clinical Practice Guidelines in Oncology. Published February 19, 2021. Accessed April 10, 2021. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf"},{"issue":"3","key":"11761_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1245\/ASO.2004.03.044","volume":"11","author":"VK Sondak","year":"2004","unstructured":"Sondak VK, Taylor JMG, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. Ann Surg Oncol. 2004;11(3):247\u201358.","journal-title":"Ann Surg Oncol."},{"issue":"7","key":"11761_CR4","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa1310460","volume":"370","author":"DL Morton","year":"2014","unstructured":"Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. N Engl J Med. 2014;370(7):599\u2013609.","journal-title":"N Engl J Med."},{"issue":"23","key":"11761_CR5","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211\u201322.","journal-title":"N Engl J Med."},{"issue":"6","key":"11761_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367.","journal-title":"Lancet Oncol."},{"issue":"19","key":"11761_CR7","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. N Engl J Med. 2017;377(19):1824\u201335.","journal-title":"N Engl J Med."},{"issue":"12","key":"11761_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa2005493","volume":"383","author":"R Dummer","year":"2020","unstructured":"Dummer R, Hauschild A, Santinami M, et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N Engl J Med. 2020;383(12):1139\u201348.","journal-title":"N Engl J Med."},{"issue":"36","key":"11761_CR9","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199\u2013206.","journal-title":"J Clin Oncol."},{"issue":"6","key":"11761_CR10","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1097\/SLA.0b013e31818fefe0","volume":"248","author":"ACJ van Akkooi","year":"2008","unstructured":"van Akkooi ACJ, Nowecki ZI, Voit C, et al. Sentinel node tumor burden according to the Rotterdam criteria is the most important prognostic factor for survival in melanoma patients: a multicenter study in 388 patients with positive sentinel nodes. Ann Surg. 2008;248(6):949\u201355.","journal-title":"Ann Surg."},{"issue":"16","key":"11761_CR11","doi-asserted-by":"publisher","first-page":"3622","DOI":"10.1200\/JCO.2001.19.16.3622","volume":"19","author":"CM Balch","year":"2001","unstructured":"Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19(16):3622\u201334.","journal-title":"J Clin Oncol."},{"issue":"5","key":"11761_CR12","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/bjs.11946","volume":"108","author":"MA El Sharouni","year":"2021","unstructured":"El Sharouni MA, Ahmed T, Witkamp AJ, et al. Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data. Br J Surg. 2021;108(5):550\u20133.","journal-title":"Br J Surg."},{"issue":"6","key":"11761_CR13","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1097\/SLA.0b013e3181b07ffd","volume":"250","author":"S Mocellin","year":"2009","unstructured":"Mocellin S, Thompson JF, Pasquali S, et al. Sentinel node status prediction by four statistical models: results from a large bi-institutional series (n = 1132). Ann Surg. 2009;250(6):964\u20139.","journal-title":"Ann Surg."},{"issue":"8","key":"11761_CR14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1245\/ASO.2006.03.019","volume":"13","author":"S Mocellin","year":"2006","unstructured":"Mocellin S, Ambrosi A, Montesco MC, et al. Support vector machine learning model for the prediction of sentinel node status in patients with cutaneous melanoma. Ann Surg Oncol. 2006;13(8):1113\u201322.","journal-title":"Ann Surg Oncol."},{"issue":"1","key":"11761_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1245\/s10434-011-1979-6","volume":"19","author":"MS Sabel","year":"2012","unstructured":"Sabel MS, Rice JD, Griffith KA, et al. Validation of statistical predictive models meant to select melanoma patients for sentinel lymph node biopsy. Ann Surg Oncol. 2012;19(1):287\u201393.","journal-title":"Ann Surg Oncol."},{"issue":"29","key":"11761_CR16","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1200\/JCO.2010.30.9567","volume":"28","author":"R Murali","year":"2010","unstructured":"Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol. 2010;28(29):4441\u20139.","journal-title":"J Clin Oncol."},{"issue":"7","key":"11761_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/DAD.0000000000001656","volume":"42","author":"S Zagarella","year":"2020","unstructured":"Zagarella S. Sentinel Lymph Node Biopsy Still Provides No Benefits for Patients With Melanoma. Am J Dermatopathol. 2020;42(7):481\u20133.","journal-title":"Am J Dermatopathol."},{"issue":"7","key":"11761_CR18","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1097\/DAD.0000000000001857","volume":"43","author":"MB Faries","year":"2021","unstructured":"Faries MB, Ascierto PA, Blank C, et al. Letter Regarding Editorial by Samuel Zagarella. Am J Dermatopathol. 2021;43(7):539\u201341.","journal-title":"Am J Dermatopathol."},{"issue":"1","key":"11761_CR19","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/cncr.22382","volume":"109","author":"SC Paek","year":"2007","unstructured":"Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer. 2007;109(1):100\u20138.","journal-title":"Cancer."},{"issue":"4","key":"11761_CR20","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.amjsurg.2017.12.009","volume":"215","author":"JM Chang","year":"2018","unstructured":"Chang JM, Kosiorek HE, Dueck AC, et al. Stratifying SLN incidence in intermediate thickness melanoma patients. Am J Surg. 2018;215(4):699\u2013706.","journal-title":"Am J Surg."},{"issue":"1","key":"11761_CR21","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/SLA.0b013e3182306c72","volume":"255","author":"R Murali","year":"2012","unstructured":"Murali R, Haydu LE, Quinn MJ, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg. 2012;255(1):128\u201333.","journal-title":"Ann Surg."},{"issue":"16","key":"11761_CR22","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1200\/JCO.2010.31.5812","volume":"29","author":"JF Thompson","year":"2011","unstructured":"Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29(16):2199\u2013205.","journal-title":"J Clin Oncol."},{"issue":"1","key":"11761_CR23","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.bjps.2019.06.020","volume":"73","author":"H Peach","year":"2020","unstructured":"Peach H, Board R, Cook M, et al. Current role of sentinel lymph node biopsy in the management of cutaneous melanoma: A UK consensus statement. J Plast Reconstr Aesthet Surg. 2020;73(1):36\u201342.","journal-title":"J Plast Reconstr Aesthet Surg."},{"issue":"2","key":"11761_CR24","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jaad.2016.08.066","volume":"76","author":"M Mandal\u00e0","year":"2017","unstructured":"Mandal\u00e0 M, Galli F, Cattaneo L, et al. Mitotic rate correlates with sentinel lymph node status and outcome in cutaneous melanoma greater than 1 millimeter in thickness: A multi-institutional study of 1524 cases. J Am Acad Dermatol. 2017;76(2):264-73.e2.","journal-title":"J Am Acad Dermatol."},{"issue":"35","key":"11761_CR25","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.18.01219","volume":"36","author":"A Hauschild","year":"2018","unstructured":"Hauschild A, Dummer R, Schadendorf D, et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-Mutant stage III melanoma. J Clin Oncol. 2018;36(35):3441\u20139.","journal-title":"J Clin Oncol."},{"issue":"19","key":"11761_CR26","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med."},{"key":"11761_CR27","unstructured":"Clinical practice guidelines for the diagnosis and management of melanoma. Australian Melanoma Guidelines. Published August 11, 2020. Accessed April 10, 2021. https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma"},{"key":"11761_CR28","unstructured":"Managing Melanoma - NICE Pathways. Published 2021. Accessed April 10, 2021. https:\/\/pathways.nice.org.uk\/pathways\/melanoma"},{"issue":"33","key":"11761_CR29","doi-asserted-by":"publisher","first-page":"5614","DOI":"10.1200\/JCO.2008.21.4882","volume":"27","author":"A Sanki","year":"2009","unstructured":"Sanki A, Uren RF, Moncrieff M, et al. Targeted high-resolution ultrasound is not an effective substitute for sentinel lymph node biopsy in patients with primary cutaneous melanoma. J Clin Oncol. 2009;27(33):5614\u20139.","journal-title":"J Clin Oncol."},{"issue":"20","key":"11761_CR30","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1056\/NEJM198005153022003","volume":"302","author":"SG Pauker","year":"1980","unstructured":"Pauker SG, Kassirer JP. The threshold approach to clinical decision making. N Engl J Med. 1980;302(20):1109\u201317.","journal-title":"N Engl J Med."},{"issue":"7","key":"11761_CR31","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s10198-017-0951-1","volume":"19","author":"S Felder","year":"2018","unstructured":"Felder S, Mayrhofer T. Threshold analysis in the presence of both the diagnostic and the therapeutic risk. Eur J Health Econ. 2018;19(7):1019\u201326.","journal-title":"Eur J Health Econ."},{"issue":"21","key":"11761_CR32","doi-asserted-by":"publisher","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","volume":"30","author":"F Azimi","year":"2012","unstructured":"Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol. 2012;30(21):2678\u201383.","journal-title":"J Clin Oncol."},{"issue":"3","key":"11761_CR33","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1245\/s10434-020-09099-w","volume":"28","author":"M Lo","year":"2021","unstructured":"Lo M, Robinson A, Wade R, et al. Extracapsular Spread in Melanoma Lymphadenopathy: Prognostic Implications, Classification, and Management. Ann Surg Oncol. 2021;28(3):1642\u201353.","journal-title":"Ann Surg Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11761-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-11761-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-11761-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,6]],"date-time":"2022-08-06T17:09:33Z","timestamp":1659805773000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-11761-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["11761"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-11761-4","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"31 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"MDM has received honoraria to present from Sanofi. RAS has received fees for professional services from F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol-Myers Squibb, Myriad Genetics, GlaxoSmithKline. Other authors have no conflicts to declare. CN has received honoraria to speak and to be on advisory boards for Novartis, Merck, EMD Sorono and Sanofi. JFT has received honoraria for advisory board participation from BMS Australia, MSD Australia, GSK and Provectus Inc, and travel and conference support from GSK, Provectus Inc and Novartis. JSZ has received fees for professional services from Merck, Amgen, Novartis, Philogen, Delcath Systems, Castle Biosciences. JSZ also has research funding through institution for Provectus, Castle Biosciences, Neracare, Philogen, Delcath Systems. None of which are pertinent to the current publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}